Industry News (Acquisitions)

AD32 Bladder Cancer Product Added to Pipeline

Published in Cancer Weekly, July 28th, 1997

Medeva PLC, London, United Kingdom, announced that it has acquired from Anthra Pharmaceuticals Inc. exclusive U.S. marketing rights to an anthracycline derivative, AD32, which is being developed for cancer of the bladder.

Anthra has already completed AD32 clinical studies in the U.S. in refractory CIS and a license application is planned for submission in the final quarter of 1997. When approved, AD32 will receive "orphan drug" status for this indication which will confer a seven year period of marketing exclusivity. Trials for the second indication are currently in progress and a license submission is scheduled for early 1999.

There are three...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-07-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry